Lantus (insulin glargine) / Sanofi - LARVOL DELTA

The GLAR-1-RANGE study: non-inferiority of EVA insulin glargine (Glargivin®) versus Lantus® in adolescents with type 1 diabetes assessed by continuous glucose monitoring metrics (EASD 2026) - "In this single center study, adolescents with T1D, Glargivin® achieved non-inferior CGM-based glycemic control compared with reference insulin glargine, with comparable TBR, TAR, GMI, and safety profiles. These findings support Glargivin® as a clinically effective and well-tolerated biosimilar basal insulin option in adolescents with T1D."

Head-to-Head • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Efficacy of de-escalation from complex insulin regimens to once-daily iGlarLixi in adults with type 2 diabetes: a pooled analysis of Soli-SWITCH and IDEAL studies (EASD 2026) - P4 | "This pooled analysis suggests there are clinical benefits in transitioning from complex insulin regimens to a once-daily treatment with iGlarLixi."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

iGlarLixi provides early glycaemic improvement without an increase in hypoglycaemia after switching from premixed insulins in adults with type 2 diabetes: a post hoc analysis of Soli-SWITCH (EASD 2026) - "Adults with T2D who switched from PI to iGlarLixi using the Soli-SWITCH titration algorithm achieved timely glycaemic improvement which was sustained to Week 12. Hypoglycaemia data at Weeks 0-4 and Weeks 5-8 indicate that this early glycaemic control did not increase the risk of hypoglycaemia during the initial titration period. These findings support iGlarLixi as an effective treatment option when switching from PI, with a favourable safety profile when appropriately titrated and monitored."

Clinical • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Post-prandial glucose excursions with iGlarLixi versus monocomponents and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: a post hoc pooled analysis (EASD 2026) - P3 | "In this pooled analysis, iGlarLixi demonstrated consistent reductions in post-prandial glucose excursions over a 24-h period in adults with T2D, with more participants achieving post-meal glucose targets."

Retrospective data • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Effectiveness, safety and healthcare resource utilisation of iGlarLixi in people with type 2 diabetes uncontrolled on basal insulin: results from the prospective real-world SOLI-ADVANCE study in Saudi Arabia (EASD 2026) - "iGlarLixi demonstrated statistically significant reductions in HbA1c in PwT2D inadequately controlled on BI. The treatment was associated with decreased hypoglycemia rates and body weight benefits. These real-world findings from Saudi Arabia support iGlarLixi as an effective and well-tolerated treatment intensification option."

Clinical • HEOR • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

OPTIMISE-GDM: Optisulin vs NovoMix30 insulin in pregnant women with gestational diabetes (ANZCTR) - P4 | N=210 | Not yet recruiting | Sponsor: Canberra Hospital Department of Endocrinology

New P4 trial • Diabetes • Gestational Diabetes • Metabolic Disorders

Pituitary tumour shrinkage and diabetic remission in two cats with Cushing syndrome treated with cabergoline. (PubMed, J Small Anim Pract) - "Diabetes mellitus was initially managed with insulin glargine (Lantus; Sanofi-Aventis, Paris, France), nutritional therapy and continuous glucose monitoring...Endocrine testing revealed non-suppressible cortisol concentrations on low-dose-dexamethasone suppression test, elevated endogenous adenocorticotrophic hormone (ACTH) concentration and pituitary enlargement on computed tomography...Serial monitoring demonstrated a decrease in endogenous ACTH concentrations and a reduction in pituitary volume of 29% of baseline (Case 1) and of 52% of baseline (Case 2) after 8 months of treatment. These findings suggest that cabergoline may be a potential medical treatment option in cats with pituitary-dependent hypercortisolism."

Journal • Cardiovascular • Cushing’s Disease • Diabetes • Endocrine Disorders • Hypertension • Metabolic Disorders • Oncology • Pituitary Gland Carcinoma

Refractory Diabetic Ketoacidosis: A Rare Case of Exogenous Insulin Antibody Syndrome (ENDO 2026) - "His diabetes was well-controlled (A1c 6.6%) on liraglutide and 70/30 insulin 10 units twice a day...Switching to Lantus and Novolog did not improve glycemic control...Mycophenolate mofetil (MMF) was started on day 15, and methylprednisolone dose was decreased to 0.6 mg/kg to reduce steroid-induced hyperglycemia. Since he still required around 200 units of insulin daily, intravenous immunoglobulin (IVIG) 500 mg/kg was administered on day 20 with plans for rituximab while inpatient...Management of EIAS can be challenging as there is no established treatment algorithm for this condition. Utilization of multiple treatment modalities targeting antibody clearance and immunosuppression may be required as exemplified by this case."

Clinical • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial (clinicaltrials.gov) - P=N/A | N=44 | Not yet recruiting | Sponsor: Hallym University

New trial • Diabetes • Metabolic Disorders • Otorhinolaryngology • Type 2 Diabetes Mellitus

Euglycemic Diabetic Ketoacidosis Triggered By Semaglutide In A Patient With Type 1 Diabetes Mellitus: A Case Of Misguided Metabolic Control (ACSM 2026) - "She was using basal insulin glargine (Lantus) 24 units daily and had recently initiated semaglutide (Wegovy) 0.5 mg weekly for weight loss—an off-label use in T1DM—eight weeks prior to presentation... Laboratory evaluation revealed metabolic acidosis with a high anion gap of 29, bicarbonate 4.6mmol/L, arterial pH 7.12, serum glucose 180 mg/dL, and positive serum ketones. Serum β-hydroxybutyrate was elevated. Renal function showed transient acute kidney injury (creatinine1.6 mg/dL)."

Clinical • Acute Kidney Injury • Addiction (Opioid and Alcohol) • Cardiovascular • Diabetes • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 1 Diabetes Mellitus

UPTAKE OF BIOSIMILARS TO INSULIN GLARGINE IN 2021-2025 IN THE UNITED STATES (ISPOR 2026) - "Insulin glargine-yfgn (Semglee®) is the first interchangeable biosimilar to Lantus® approved by the U.S. FDA in July 2021. A second biosimilar, insulin glargine-aglr Rezvoglar®), was approved in December 2021 and designated interchangeable status in November 2022... Mild uptake of insulin glargine biosimilars in the insured populations was observed within the first 4 years of marketing in the U.S. Further exploration of factors to access such as provider and patient education, policy implementation, and reimbursement reform is warranted to foster stronger biosimilar adoption."

Diabetes • Metabolic Disorders

COMPARISONS OF MEDICAL AND PRESCRIPTION DRUG EXPENDITURES BETWEEN AMERICANS WHO USED INSULIN GLARGINE LANTUS AND ITS INTERCHANGEABLE BIOSIMILAR SEMGLEE (ISPOR 2026) - "As a biosimilar, Semglee led to lower total and OOP prescription drug expenditures for both healthcare system and consumers compared to Lantus, without increasing total medical expenditures. The higher OOP medical expenditures for Semglee users might be due to private insurance plan cost-sharing benefit design. Findings of this study call for real-world evidence research to compare effectiveness and safety between Lantus and its biosimilars for further adoption of biosimilars."

Initiation of the interchangeable biosimilar insulin glargine-yfgn among older adults. (PubMed, Am J Manag Care) - "Insulin glargine-yfgn use among older adults is low despite its cost-effectiveness. Overcoming barriers related to prescribing patterns, formulary placement and reimbursement challenges, and pharmacy channels could improve insulin glargine-yfgn adoption, reducing diabetes care costs."

Journal • Retrospective data • Diabetes • Metabolic Disorders

Cytomegalovirus Infection as a Trigger for Severe Glycemic Decompensation in a Pre-Existing Diabetic Patient After Heart Transplantation: A Case Report (ISHLT 2026) - "Tacrolimus was initiated on July 1, replacing cyclosporine due to subtherapeutic levels...Intravenous ganciclovir was started on July 15.Following CMV detection, the patient developed persistent hyperglycemia requiring progressive escalation of insulin doses from Lantus 16 U/day to 62 U/day, and prandial insulin from 0-10 U to 18-22-12 U, despite prednisone taper from 40 mg to 10 mg daily...While most literature addresses de novo diabetes post-transplant, this case suggests CMV can also significantly destabilize pre-existing diabetes.Summary CMV infection should be considered in the differential diagnosis of abrupt glycemic deterioration after heart transplantation, even in patients with pre-existing diabetes. Close monitoring of glucose and CMV PCR is warranted, as prompt antiviral therapy and immunosuppression adjustment may mitigate metabolic complications."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Cytomegalovirus Infection • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Transplantation • Type 2 Diabetes Mellitus

EARLY GLYCAEMIC IMPROVEMENT WHEN SWITCHING TO IGLARLIXI FROM PREMIXED INSULINS (PI) IN ADULTS WITH TYPE 2 DIABETES (T2D): A POST HOC ANALYSIS OF SOLI-SWITCH (ATTD 2026) - P4 | "In adults with T2D who switched from PI to iGlarLixi, glycaemic control improved in the first weeks of transitioning (Weeks 0–3) and continued to improve to Week 12. Funded by Sanofi. Previously presented at ADA and EASD"

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

GLYCAEMIC CONTROL IMPROVEMENTS IN A PATIENT WITH TYPE 1 DIABETES AND CYSTIC FIBROSIS: UTILITY OF ADVANCED HYBRID CLOSED-LOOP MM780G INSULIN PUMP (ATTD 2026) - "With CF and bronchiectasis, a family history of CF-related mortality, pre-pump management included basal insulin (Lantus 26 units) and bolus insulin with ICR 1:10 and ISF 50... This case demonstrates that hybrid closed-loop insulin delivery can substantially improve glycemic outcomes in patients with T1D and complex comorbidities as Cystic Fibrosis, where traditional insulin regimens may be insufficient. CGMs sensors provide valuable real time insight into patient glycaemic patterns. Early adoption of automated insulin delivery should be considered in similar high-risk populations."

Clinical • Metastases • Bronchiectasis • Cystic Fibrosis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Type 1 Diabetes Mellitus

EFFICACY OF DE-ESCALATION FROM MULTIPLE DAILY INJECTIONS TO ONCE-DAILY IGLARLIXI IN ADULTS WITH TYPE 2 DIABETES: A POOLED ANALYSIS OF IDEAL AND SOLI-SWITCH STUDIES (ATTD 2026) - "This pooled analysis suggests there are clinical benefits in transitioning from complex insulin regimens to a once-daily treatment with iGlarLixi. Funded by Sanofi."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (clinicaltrials.gov) - P2 | N=20 | Completed | Sponsor: Alexandria University

New P2 trial • Dermatology • Immunology • Pemphigus Vulgaris

NN1436-7727: A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 Diabetes (clinicaltrialsregister.eu) - P4 | N=204 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P4 trial • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

CVC-22-001: A phase 1 glucose clamp trial investigating the bioequivalence of CVC-001 cartridge and vial formulations vs U.S.-Licensed Lantus in healthy male volunteers (clinicaltrialsregister.eu) - P1 | N=96 | Recruiting | Sponsor: Civica Inc.

New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Examining the Influence of Nurse Staffing on Delayed Insulin Administration in Acute Care Settings Using EHR and BCMA Data. (PubMed, AMIA Annu Symp Proc) - "Long-acting insulin (Lantus) (64.6%) had more delays than other types of insulin, suggesting that the pharmacokinetics properties of these insulins may influence how nurses prioritized their insulin administrations...Lastly, we found patients with delayed insulin administration had poorer glycemic control. Our study demonstrates the need for evidence-based staffing that enables nurses to deliver timely insulin administration during high-demands periods."

Journal • Diabetes • Metabolic Disorders

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (clinicaltrials.gov) - P3 | N=7850 | Completed | Sponsor: GRADE Study Group | N=5047 ➔ 7850

Enrollment change • HEOR • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=324 | Not yet recruiting | Sponsor: Yanbing Li | Initiation date: Oct 2025 ➔ Mar 2026

Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison chart: Some available insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus